GlassScriptPhysician profile
Irfan U Rahim
NPI 1588612980
$1,406.88
in general payments reported to CMS, 2019-2025
15 companies · $374 in 2025
The $374 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $71.54 · 2021: $91.10 · 2022: $136 · 2023: $321 · 2024: $230 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $924.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $388.72 | 2019-2025 | Bexsero, Penmenvy, Menveo |
| Corium, LLC | $322.82 | 2022-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $108.68 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $96.41 | 2019-2023 | Vaxneuvance, Gardasil 9, M-M-R II |
| Sanofi Pasteur INC. | $80.82 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.86 | 2019-2021 | |
| Genentech USA, INC. | $64.33 | 2024 | Xolair |
| Pfizer INC. | $58.66 | 2021-2024 | |
| Shire North American Group INC | $57.15 | 2019 | |
| Ironshore Pharmaceuticals INC. | $56.16 | 2019 | |
| Tris Pharma INC | $24.74 | 2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $24.23 | 2024 | Qelbree |
| Sobi, INC | $20.58 | 2023 | |
| Seqirus USA INC | $17.73 | 2023 | Flucelvax Quadrivalent |
| Adlon Therapeutics L.P. | $15.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irfan Rahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.